Johnson & Johnson has posted a mixed bag of results for the fourth quarter or 2014, with a hefty drop in profit masking underlying growth in sales and a strong performance by prescription drugs.

Unfavourable currency impacts helped push fourth-quarter profit down 28% to $2.5 billion, or $0.89 per share, the healthcare giant said.

Worldwide sales slipped 0.6% to $18.3 billion, with a near 7% drop in international revenues, though it was noted that excluding the net impact of acquisitions and divestitures organic sales growth was actually 6.7%.

Turnover from J&J’s Pharmaceuticals segment helped buoy overall performance, jumping almost 10% to just shy of $8 billion, while those from both Consumer and Medical Devices units fell, by 3.9% to $3.6 billion and 9% to $6.7 billion, respectively.

Full-year sales grew 4.2% to $74.3 billion, helping to drive a 20% increase in net earnings to $16.3 billion.

Here’s the full release.